# scientific reports



## **OPEN** PastoCovac and PastoCovac Plus as protein subunit COVID-19 vaccines led to great humoral immune responses in BBIP-CorV immunized individuals

Amitis Ramezani<sup>1</sup>, Rahim Sorouri<sup>2</sup>, Saiedeh Haji Maghsoudi<sup>3,4</sup>, Sarah Dahmardeh<sup>5</sup>, Delaram Doroud<sup>6</sup>, Mona Sadat Larijani<sup>1⊠</sup>, Sana Eybpoosh<sup>7</sup>, Ehsan Mostafavi<sup>7</sup>, Alireza Olyaeemanesh<sup>8</sup>, Mostafa Salehi-Vaziri<sup>9</sup>, Anahita Bavand<sup>1</sup>, Ghazaleh Zarghani<sup>5</sup>, Ladan Moradi<sup>1</sup>, Fatemeh Ashrafian<sup>1</sup>, Fahimeh Bagheri Amiri<sup>7</sup>, Parisa Mashayekhi<sup>10</sup>, Zahra Tahmasebi<sup>7</sup> & Alireza Biglari<sup>11</sup>

The optimal booster vaccine schedule against COVID-19 is still being explored. The present study aimed at assessment of the immunogenicity and antibody persistency of inactivated-virus based vaccine, BBIP-CorV and protein-subunit based vaccines, PastoCovac/Plus through heterologous and homologous prime-boost vaccination. Totally, 214 individuals who were previously primed with BBIBP-CorV vaccines were divided into three arms on their choice as heterologous regimens BBIBP-CorV/PastoCovac (n = 68), BBIBP-CorV/PastoCovac Plus (n = 72) and homologous BBIBP-CorV (n = 74). PastoCovac booster recipients achieved the highest rate of anti-Spike IgG titer rise with a fourfold rise in 50% of the group. Anti-RBD IgG and neutralizing antibody mean rise and fold rise were almost similar between the PastoCovac and PastoCovac Plus booster receivers. The antibody durability results indicated that the generated antibodies were persistent until day 180 in all three groups. Nevertheless, a higher rate of antibody titer was seen in the heterologous regimen compared to BBIP-CorV group. Furthermore, no serious adverse event was recorded. The protein subunit-based booster led to a stronger humoral immune response in comparison with the BBIP-CorV booster receivers. Both the protein subunit boosters neutralized SARS-CoV-2 significantly more than BBIP-CorV. Notably, PastoCovac protein subunit-based vaccine could be successfully applied as a booster with convenient immunogenicity and safety profile.

SARS-CoV-2 has still remained an unsolved medical matter due to the variants with the potency of immune escape and waning of elicited immunity either natural or vaccine-induced, leading to a growing number of vaccine-breakthrough incidents and re-infections globally<sup>1-4</sup>. Mass vaccination programs through different platforms are held with the aim of reducing the burden of COVID-19<sup>5,6</sup>.

Inactivated virus-based vaccine, BBIBP-CorV (Sinopharm), was among the first approved COVID-19 vaccines with successful safety profile. BBIP-CorV was the first administrated vaccine in Iran which the vast majority

<sup>1</sup>Clinical Research Department, Pasteur Institute of Iran, No 69, Pasteur Ave., Tehran, Iran. <sup>2</sup>IPI Directorate, Pasteur Institute of Iran, Tehran, Iran. <sup>3</sup>Modeling in Health Research Center, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran. <sup>4</sup>Department of Biostatistics and Epidemiology, School of Public Health, Kerman University of Medical Sciences, Kerman, Iran. <sup>5</sup>Department of Vaccination, Pasteur Institute of Iran, Tehran, Iran. <sup>6</sup>Quality Control Department, Production and Research Complex, Pasteur Institute of Iran, Tehran, Iran. <sup>7</sup>Department of Epidemiology and Biostatistics, Research Centre for Emerging and Reemerging Infectious Diseases, Pasteur Institute of Iran, Tehran, Iran. <sup>8</sup>Health Equity Research Centre and National Institute of Health Research, Tehran University of Medical Science, Tehran, Iran. <sup>9</sup>COVID-19 National Reference Laboratory, Pasteur Institute of Iran, Tehran, Iran. <sup>10</sup>Department of Molecular Medicine, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran. <sup>11</sup>School of Medicine, Tehran University of Medical Sciences, Enghelab Street, P.O. BOX 14155-6559, Tehran, Iran. <sup>™</sup>email: mona.sadat@gmail.com; biglari63@hotmail.com

of the population were primed with it<sup>7.8</sup>. Although strong humoral immune response induction was seen in primary results, later studies showed that protective antibodies are not durable in some individuals after two doses of vaccination<sup>9,10</sup>.

Moreover, the emergence of the Omicron variant, has brought serious concerns regarding vaccine effectiveness and antibody persistency. Antibody fading have been reported after COVID-19 vaccination leading to reduced protection against both infection and hospitalization<sup>11-14</sup>.

In order to restore the immune responses, booster injections have been recommended though the optimal interval, dose and strategy are being explored. A booster dose could be administrated in a homologous or heterologous regimen<sup>15-17</sup>. In case of COVID-19, heterologous boosting has been recommended by some studies proposing that mix-and-match strategy would elicit and recover the immune responses better than the homologous agent. Owing to recent published data, a booster dose of a different type like mRNA or vector-based vaccines are more sufficient and could strongly induce specific antibodies against the virus<sup>17-19</sup>.

PastoCovac (Soberana 02) is manufactured in Pasteur Institute of Iran in collaboration with Finlay Vaccine Institute of Cuba. It is a recombinant protein vaccine composing a highly immunogenic region of SARS-CoV-2 Spike (RBD) conjugated to the tetanus toxin<sup>20</sup>. PastoCovac Plus (Soberana Plus) is also the booster dose of the candidate vaccine [dimer of RBD (50  $\mu$ g)]<sup>20-22</sup>. The safety and immunogenicity of both vaccines as the priming and boosting doses were excellent<sup>20,21</sup>.

PastoCovac as the primary vaccine dose has the approval to be applied against SARS-CoV-2 with a high immunogenicity. The most commonly used vaccine against COVID-19 in Iran has been BBIBP-CorV. According to the need for administration of an optimum booster, identifying the booster vaccine which could provide safely stronger immunogenicity profile is important.

Hereby, we aimed at evaluation of immunogenicity and persistency of protein subunit vaccines (PastoCovac/ Plus) and BBIBP-CorV as booster doses in Iranian population who were primarily vaccinated with two doses of BBIBP-CorV.

#### Results

**Participants.** Totally, 214 volunteers were evaluated including 108 males and 106 females. Twenty-five of the participants had at least one underlying disease and 36 individuals had a COVID-19 history (Table 1). There was no significant difference between BBIBP-CorV, PastoCovac and PastoCovac Plus booster groups in terms of mean age, sex and COVID-19 history (P>0.05).

The mean (SD) of the days since the last BBIBP-CorV (the 2nd dose) to get the booster shot (the 3rd dose) was 144.4 (28.1) for BBIBP-CorV/BBIBP-CorV group and 137.8 (25.4) for the both heterologous groups which did not show any significant difference between the three groups (*P*: 0.39).

**Immunogenicity evaluation.** Anti-SARS-CoV-2 antibodies were evaluated 21 days after the booster shot. The specific antibodies were tracked and the geometric mean of antibodies' titer, fold rise and also fourfold rise were compared with the obtained values before the injection.


All the seronegative individuals became seropositive after the booster shot of any type on day 21. PastoCovac booster recipients reached the highest anti-Spike IgG titer rise [717.0 (95% CI 485.4–1059.3)] among whom a fourfold rise of 50% was achieved (Table 2, Fig. 1.). Neutralizing and anti-RBD IgG antibody mean rise and fold rise were almost similar between the PastoCovac and PstoCovac Plus booster receivers (Table 2, Figs. 2 and 3). In contrast, BBIBP-CorV booster led to the lowest antibody mean rise, fold-rise and four-fold rise regarding anti-Spike, neutralizing and anti-RBD Abs (Figs. 1, 2 and 3).

Feature	BBIBP-CorV	PastoCovac Plus	PastoCovac				
Population	(n=74)	(n=72)	(n=68)	P-value			
Female	37 (50.0%)	35 (48.6%)	34 (50.0%)	0.982 <sup>b</sup>			
Male	37 (50.0%)	37 (51.4%)	34 (50.0%)				
Age							
Mean (SD)	43.0* (14.6)	41.9 (12.8)	41.3 (13.8)	0.775 <sup>a</sup>			
≤ 50	49 (66.2%)	53 (73.6%)	48 (70.6%)	0.618 <sup>b</sup>			
> 50	25 (33.8%)	19 (26.4%)	20 (29.4%)				
COVID history							
No	60 (81.1%)	63 (87.5%)	55 (80.9%)	0.484 <sup>b</sup>			
Yes	14 (18.9%)	9 (12.5%)	13 (19.1%)				
Underlying disease							
No	62 (83.8%)	65 (90.3%)	62 (91.2%)	0.320 <sup>b</sup>			
Yes	12 (16.2%)	7 (9.7%)	6 (8.8%)	0.520			

**Table 1.** Demographic and baseline characteristics of the participants. SD standard deviation. <sup>a</sup>One-wayANOVA test, <sup>b</sup>Chi-square test. \*A P value > 0.05 was considered significant.

Antibody's feature	BBIBP-CorV	PastoCovac Plus	PastoCovac	P-value					
Anti-spike IgG									
Titer rise GMT (95% CI)	32.8 (20.2, 53.3)	352.6 (261.5, 475.5)	717.0 (485.4, 1059.3)	<0.001 <sup>a</sup>					
Fourfold rise (n %)	13 (24.3%)	42 (63%)	32 (50%)	<0.001 <sup>b</sup>					
Fold rise GMT (95% CI)	2.5 (1.9, 3.3)	8.7 (6.1, 12.5)	7.5 (4.8, 11.6)	<0.001 <sup>a</sup>					
Neutralizing Ab									
Titer rise GMT (95% CI)	0.9 (0.5, 1.5)	3.7 (2.3, 6.0)	2.9 (1.8, 4.6)	0.004 <sup>a</sup>					
4-old rise (n %)	2 (3.2%)	13 (19.7%)	11 (17.5%)	0.261 <sup>b</sup>					
Fold rise GMT (95% CI)	1.3 (1.1, 1.5)	2.8 (1.8, 4.2)	2.0 (1.4, 2.7)	0.054 <sup>a</sup>					
Anti-RBD									
Titer rise GMT (95% CI)	31.0 (20.5, 46.7)	916.3 (614.0, 1367.5)	816.1 (599.3, 1111.4)	<0.001 <sup>a</sup>					
Fourfold rise (n %)	10 (16.1%)	48 (72%)	39 (61.9%)	<0.001 <sup>b</sup>					
Fold rise GMT (95% CI)	2.1 (1.6, 2.7)	21.5 (12.5, 37.3)	12.2 (7.5, 20.0)	<0.001 <sup>a</sup>					

**Table 2.** Evaluation of elicited antibodies against ARS-CoV-2 after the booster shots on day 21. *GMT* geometric mean titer, *CI* confidence interval. <sup>a</sup>Kruskal-Wallis test, <sup>b</sup>Chi-square test. Bold P values are indicated statistically significant.




**Figure 1.** Anti-SARS-CoV-2 Spike antibody titers before and after injection of the three boosters during 6-month follow-up. Median and 95% confidence intervals are shown on the diagram. P-values were obtained using pairwise for Friedman test. Asymptotic significances (2-sided tests) are displayed, with a type I error of 0.05. Significance values have been adjusted for multiple comparisons using Bonferroni correction.


.....

**Long-term humoral immunity assessment.** The persistency of generated specific antibodies against SARS-CoV-2 was tracked through three different window times which were compared to time before the booster injection and 21 days after it (Table 3 and Figs. 1, 2 and 3).

Although the antibodies' titers declined over the time, they were still in an acceptable level of persistency during the 6 months. According to BA.5 variant peak in Iran in this window time, a high rate of infection was recorded especially among BBIP-CorV vaccinated individuals. This led to an increase in antibody titers among BBIP-CorV group on day 180 which indicates the higher rate of COVID-19 incidence in comparison with Pasto-Covac/Plus groups though the confirmed COVID-19 infected cases with an episode of infection from day 90 to day 180 were excluded from the associated analysis. Neutralizing antibody showed better stability in comparison with anti-Spike and anti-RBD IgGs over the time.



**Figure 2.** Anti-SARS-CoV-2 Neutralizing antibody titers before and after injection of the three boosters during 6-month follow-up. Median and 95% confidence intervals are shown on the diagram. P-values were obtained using pairwise for Friedman test. Asymptotic significances (2-sided tests) are displayed, with a type I error of 0.05.



**Figure 3.** Anti-SARS-CoV-2 antibody titers before and after injection of the three boosters during 6-month follow-up. Median and 95% confidence intervals are shown on the diagram. P-values were obtained using pairwise for Friedman test. Asymptotic significances (2-sided tests) are displayed, with a type I error of 0.05. Significance values have been adjusted for multiple comparisons using Bonferroni correction.

Vaccine group (booster type)	Before	Day 21	Day 60	Day 90	Day 180	P-value <sup>b</sup>			
Anti SARS-CoV-2 spike antibody (geometric mean, 95% CI)									
BBIBP-CorV	36.1 (25.1, 51.9)	101.9 (70.4, 147.3)	117.0 (81.2, 168.4)	73.5 (42.7, 126.6)	83.7 (46.2, 151.5)	< 0.001			
PastoCovac-Plus	72.3 (43.8, 119.4)	574.2 (438.5 , 751.9)	457.0 (325.0, 642.7)	337.0 (219.9, 516.4)	253.3 (144.7, 443.5)	< 0.001			
PastoCovac	210.7 (128.6, 345.3)	1,475.6 (1,092.4 , 1,993.3)	524.7 (397.9, 691.9)	247.3 (179.4, 340.9)	134.2 (88.1, 204.2)	< 0.001			
P-value <sup>a</sup>	<0.001	< 0.001	< 0.001	<0.001	0.012				
Anti SARS-CoV-2 neutralizing antibody (geometric mean, 95% CI)									
BBIBP-CorV	14.8 (10.3, 21.1)	25.5 (21.3, 30.5)	23.9 (18.4, 31.1)	24.7 (18.0, 33.8)	31.3 (28.5, 34.2)	0.001			
PastoCovac-Plus	13.4 (9.0, 20.1)	34.6 (33.5, 35.6)	30.4 (24.4, 37.9)	32.7 (30.3, 35.3)	32.3 (30.3, 34.4)	< 0.001			
PastoCovac	18.3 (13.3, 25.0)	34.9 (34.4, 35.4)	35.6 (34.9, 36.4)	33.9 (32.9, 34.9)	29.7 (24.3, 36.4)	< 0.001			
P-value <sup>a</sup>	0.648	< 0.001	< 0.001	0.344	0.703				
Anti SARS-CoV-2 RBD antibody (geometric mean, 95% CI)									
BBIBP-CorV	52.9 (34.7, 80.7)	115.6 (81.4, 164.0)	81.1 (51.3, 128.4)	48.3 (28.5, 81.9)	76.5 (38.9, 150.1)	< 0.001			
PastoCovac-Plus	75.9 (41.0, 140.4)	1432.7 (1,029.6 , 1993.8)	465.7 (319.4 , 679.1)	277.2 (170.0, 452.0)	160.8 (94.9, 272.6)	< 0.001			
PastoCovac	117.3 (69.9 ,196.6)	1259.6 (962.4, 1,648.6)	415.8 (308.3 , 560.9)	278.6 (188.8, 411.2)	103.5 (74.1, 144.6)	< 0.001			
P-value <sup>a</sup>	0.055	< 0.001	< 0.001	< 0.001	0.081				

**Table 3.** SARS-CoV-2 specific antibodies titer trend during the 6-month follow-up. *CI* confidence interval. <sup>a</sup>Kruskal-Wallis test, <sup>b</sup>Friedman test. Bold P values are indicated statistically significant.

.....

Furthermore, upon adjustment of variables including sex, age, COVID-19 history and underlying disease, the median of anti-Spike IgG was higher in PastoCovac and PastoCovac Plus than BBIP-CorV on days 60, 90 and 180 (Supplementary data).

Comparison of neutralizing antibody titer was done on days 21, 60, 90 and 180 and it was found that the baseline level of neutralizing antibody on day 180 in individuals still has a higher level than day zero. (Table 3, Fig. 2). The mean titer of neutralizing antibody on day 180 is similar in all three groups. There was no significant difference in the reduction of neutralizing antibody between the three groups during 90–180 days after the booster shot.

**Neutralization assay.** The virus neutralization potency of the induced antibodies was assessed through cVNT50 test on 18 randomly selected sera samples against Wuhan and Omicron variants. The results showed that after PastoCovac booster dose, significant increases were observed against Wuhan (P < 0.001) and Omicron variant (P < 0.01) compared to homologous BBIBP-CorV regimen (Fig. 4A). In line with this, PastoCovac Plus also showed significantly higher neutralization potency than BBIBP-CorV shot against the both clades (Fig. 4B).


**Adverse events.** No side effect was recorded within 30 min post the booster injections of any type. The safety assessment was done on day 7 through the phone call which showed that pain at the injection site was the only local event in 15.9%, 11.3% and 4.5% of the participants in PastoCovac Plus, BBIBP-CorV and PastoCovac groups, respectively. Furthermore, the systemic adverse events were observed in 19.4% of BBIBP-CorV, 14.3% of PastoCovac Plus recipients among which headache and weakness were the most common systemic adverse events. There was no recorded adverse event on day 21 during the period of 3 weeks after the injection.

#### Discussion

Traditional vaccine strategies were primarily developed applying the attenuated or inactivated whole virus particles against COVID-19. However, later studies demonstrated that this method does not provide the preferable protection<sup>14,23</sup>. Subunit vaccines based on the selected fragments have the potency to elicit antibody responses by only carrying the required antigenic components of the virus<sup>24,25</sup>.

PastoCovac as a protein subunit and primary series vaccine has shown great results in the clinical trials<sup>26,27</sup>. The present study shows excellent immunogenicity and the persistency of the induced antibodies of this vaccine as a booster shot in primarily vaccinated individuals with a 2-dose of BBIBP-CorV. The assessment of the antibody level on the first 21-day proved that PastoCovac is highly immunogenic through which fold rises of 7.5, 12.2 and 2.9 was achieved regarding SARS-CoV-2 anti-Spike, anti-RBD and neutralizing antibodies, respectively. Although the results of the seronegative individuals showed that the three applied boosters led to a 100% seropositivity, the four-fold rise regarding anti-Spike, neutralizing and anti-RBD antibodies were different between the homologous group and heterologous ones which highlights the great humoral immunity induction of PastoCovac and PastoCovac Plus as booster shots on an inactivated vaccine. Furthermore, the induced neutralizing antibodies examination proved that PasoCovac/Plus significantly neutralized SARS-CoV-2 variants.

In a study, NVSI-06-07 (recombinant protein-based vaccine) was evaluated as a booster dose in BBIBP-CorV vaccinated participants in parallel with BBIBP-CorV/BBIBP-CorV as the controls. The results showed that the induction of neutralizing antibodies against SARS-CoV-2 was higher in the protein-based booster receivers on day 28<sup>28</sup>. In our study, the neutralizing antibody titer rise in PastoCovac and PastoCovac Plus groups was 2.9



**Figure 4.** Comparison of virus neutralizing test between the applied boosters. Sera from 18 vaccinated individuals with complete schedule were evaluated (cVNT50: GMT, 95% CI) against variants Wuhan G clade and Omicron BA.5 variant. P values represent the statistic differences. (**A**) Two doses BBIBP-CorV + one dose PastoCovac; (**B**) Two doses BBIBP-CorV + one dose PastoCovac Plus in comparison with three doses of BBIBP-CorV.

and 3.7 whereas in BBIBP-CorV with a rate of 0.9 on day 21. What is more, the highest rate of anti-Spike titer in PastoCovac receivers 717.0 followed by PastoCovac Plus 352.6 which is comparable with BBIBP-CorV recipients 32.8. In addition, anti-RBD titer rise was calculated as 916.3, 816.1 and 31.0 in PastoCovac Plus, PastoCovac and BBIBP-CorV groups.

The study from Cuba also showed that two doses of SOBERANA 02 (PastoCovac) combined with SOBER-ANA Plus (PastoCovac Plus) increased neutralizing antibodies which were detectable up to 8 months after the third dose. Moreover, sera samples of the vaccinated individuals neutralized the variants of concerns including Alpha, Beta, Delta, and Omicron<sup>29</sup>. The neutralization assay in our study also showed that both PastoCovac and PastoCovac Plus boosters neutralized Wuhan clade and also Omicron variant significantly more powerful than BBIBP-CorV.

Optimal boosting strategies are supposed to induce specific antibodies which are durable in order to the long-term pandemic control. Therefore, the persistency of humoral immune response has also come to attention according to the SARS-CoV-2 new waves of infection. The secondary outcomes of the present study proved that all the boosters led to a persistent antibody induction 180 days post the injection. The heterologous patterns resulted in a higher antibody titer mean compared to BBIP-CorV/ BBIP-CorV group during the 6-month follow-up. Interestingly, an increasing trend of antibodies is observed in only BBIP-CorV group on day 180. Nevertheless, the case-following indicated that the rate of infection was more prevalent in this group.

Our results indicate that booster shots of a different vaccine type against COVID-19 could lead to strong humoral immune responses and protein vaccines have the advantage of flexibility in cooperating with other vaccine platforms especially inactivated virus based types. However, in this study the protein subunit vaccine, PastroCovac/Plus, was only evaluated as a booster dose on individuals who were primed with inactivated virus vaccine which could be considered as a limitation though on the other study Adeno-based vaccine has been also considered (under review data). Moreover, PastoCovac vaccine was not applied as a priming dose in the present study which might have stronger humoral immune response than BBIP-CorV primed population due to the previously conducted study which assessed this issue (under review data).

#### Conclusion

Administration of the same or different booster vaccines against COVID-19 in vaccinated individuals with BBIBP-CorV resulted in an acceptable level humoral immunity against COVID-19, however, protein subunit boosters showed a higher level of antibody induction with a great potency of SARS-Cov-2 neutralization ability

in the present study beside an excellent safety profile. PastoCovac protein subunit vaccine, as a main vaccine dose against SARS-CoV-2, is hereby presented highly immunogenic with no safety concern as a booster shot. In other words, PastoCovac and PastoCovac Plus have similar immunogenicity, and safety profile as a booster dose and could be applied alternatively. Furthermore, the durability of the elicited antibodies proved the high rate of the elicited antibodies after six months.

#### Material and methods

**Study design.** This study is a non-randomized, open-labeled parallel clinical trial performed on individuals of Pasteur Institute of Iran with a 180-day follow-up schedule. Eligible individuals aged from 18 to 80 years with controlled underlying disease were enrolled in the study who had received their first two-dose of BBIBP-CorV vaccine ( $28 \pm 5$  interval), 3–6 months prior to the admission.

The exclusion criteria included pregnant or breast-feeding women; individuals who got any vaccines in addition to two doses of BBIBP-CorV, presenting SARS-CoV-2 symptoms, having fever at the time or in a week prior to the enrollment and those under the immunosuppressive treatment in one month before the trial.

The eligible volunteers were free to choose one of the three boosters as PastoCovac ( $25 \ \mu g$  of Tetanus toxin conjugated to RBD), PastoCovac Plus ( $50 \ \mu g$  RBD-dimer) or BBIBP-CorV ( $6.5 \ U$  of inactivated SARS-CoV-2 antigen).

The study was approved by the Iran National Committee for Ethics in Biomedical Research (ethics code number: IR.NREC.1400.020) and was registered at the Iranian Registry of Clinical Trials (IRCT20131221015878N4, 26/02/2022).

All the participants were provided with the informed consent form before enrollment and all the protocol was performed according to the Declaration of Helsinki (Fortaleza, 13th Oct, 2013).

**Sampling and antibody assessment.** Blood samples were collected before the booster shot and also on days 21, 60, 90 &180 post vaccination at site. Upon serum isolation, assessment of the generated antibodies was investigated with titers of anti-Spike IgG [Anti-SARS-CoV-2 Quantivac ELISA (IgG) (Euroimmun, Lübeck, Germany)], anti-RBD IgG [Anti-SARS-CoV-2 RBD (IgG), IDEALTASHKHIS, Iran] and neutralizing antibody (SARS-CoV-2 Neutralizing Ab IDEALTASHKHIS, Iran).

**Virus neutralizing test.** Conventional neutralizing antibody titers (cVNT50) was evaluated on randomly selected samples<sup>30</sup>. Briefly, the samples were inactivated at 56 °C for 30 min. Vero cells were seeded in DMEM containing 10% FBS. Serial dilution of sera samples was prepared. Then 50  $\mu$ l of each serum was mixed with 50  $\mu$ l of 100 TCID<sub>50</sub> of SARS-CoV-2 (D clade and BA.5 variant) and incubated at room temperature for an hour. Next, the prepared mixture was added into the wells containing monolayers of Vero cells for 60 min incubation at 37 °C. The control wells were as a well without the mixture of serum and virus, one well without any serums, and one well without any cells. After the incubation time and supernatant removal, the cells were washed with DMEM. After 72 h of maintaining in DMEM at 37 °C, the CPE was assessed applying an inverted microscope and the titer of neutralizing antibodies was evaluated in accordance to the highest serum dilution in which the virus was neutralized in 50% of the wells.

**Statistical analysis.** The level of antibodies was assessed before and after the injection by geometric mean and standard deviation. Moreover, fourfold increase in antibody concentration over the baseline antibody was also investigated.

In order to calculate the antibodies fold-rise, the titer of antibodies after the booster shot was divided by its titer before the injection. The geometric mean of the calculated numbers was determined. In addition, antibody titer after the booster shot minus the antibody titer before the booster shot was calculated to achieve the pure titer of the antibody rise.

One way variance analysis and chi-squared test were applied to assess the variables including age, gender and COVID-19 history.

Chi-squared test was applied to compare the four-fold rise between the three groups. Friedman test was applied to assess the antibodies' titer over the time. In addition, Logistic Regression models and Generalized Estimating Equations were used to assess the impact of the vaccines on the antibodies' induction.

In each study arm, the frequency and frequency percentage of the solicited and unsolicited adverse events were calculated applying Chi-squared test. P values < 0.05 was considered statistically significant.

**Outcomes.** The immunogenicity assessment was done regarding anti-SARS-CoV-2 RBD IgG, anti-SARS-CoV-2 Spike IgG and neutralizing antibodies between the three vaccine types on days 0, and 21. In addition, the safety assessment of the booster doses was also evaluated 30 min after the booster injection, on day 7 (via a phone call) and day 21 (at the site) regarding solicited systemic and local adverse events. The persistency of humoral immune responses were followed on days 60, 90 and 180.

#### Data availability

Data that support the findings of this study are available upon reasonable request to the corresponding author.

Received: 4 December 2022; Accepted: 13 May 2023 Published online: 18 May 2023

#### References

- Abu-Raddad, L. J. et al. SARS-CoV-2 reinfection in a cohort of 43,000 antibody-positive individuals followed for up to 35 weeks. medRxiv 11, 05005 (2021).
- Dejnirattisai, W. et al. SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. Cell 185(3), 467–84.e15 (2022).
- Salehi-Vaziri, M. et al. SARS-CoV-2 re-infection rate in Iranian COVID-19 cases within one-year follow-up. Microbial Pathogenes. 161, 105296 (2021).
- Sofian, M. et al. SARS-CoV-2 viral shedding and associated factors among COVID-19 inpatients and outpatients. Interdiscip. Perspect. Infect. Dis. 2022, 1411106 (2022).
- Lurie, N., Saville, M., Hatchett, R. & Halton, J. Developing covid-19 vaccines at pandemic speed. N. Engl. J. Med. https://doi.org/ 10.1056/NEJMp2005630 (2020).
- Menni, C. et al. COVID-19 vaccine waning and effectiveness and side-effects of boosters: A prospective community study from the ZOE COVID study. Lancet. Infect. Dis. 22(7), 1002–1010 (2022).
- 7. Graña, C. et al. Efficacy and safety of COVID-19 vaccines. Cochrane Database Syst. Rev. 12(12), Cd015477 (2022).
- 8. Wang, H. *et al.* Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2. *Cell* **182**(3), 713–21.e9 (2020).
- 9. Choudhary, H. R. *et al.* Persistence of antibodies against spike glycoprotein of SARS-CoV-2 in healthcare workers post double dose of BBV-152 and AZD1222 vaccines. *Front. Med.* **8**, 778129 (2021).
- 10. ICMR study shows significant drop in Covid antibodies within 4 months after vaccination [Internet]. India Today (2021) [cited 2020/04/04].
- 11. Antonelli, M., Pujol, J. C., Spector, T. D., Ourselin, S. & Steves, C. J. Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2. *Lancet* **399**(10343), 2263–2264 (2022).
- 12. Chenchula, S., Karunakaran, P., Sharma, S. & Chavan, M. Current evidence on efficacy of COVID-19 booster dose vaccination against the Omicron variant: A systematic review. J. Med. Virol. 94(7), 2969–2976 (2022).
- Salehi-Vaziri, M. et al. Clinical characteristics of SARS-CoV-2 by re-infection vs. reactivation: A case series from Iran. Eur. J. Clin. Microbial. Infect. Dis. 40(8), 1713–9 (2021).
- 14. Fotouhi, F. et al. Prolonged viral shedding and antibody persistence in patients with COVID-19. Microbes Infect. 23, 104810 (2021).
- 15. Assawakosri, S. *et al.* Neutralizing activities against the omicron variant after a heterologous booster in healthy adults receiving two doses of CoronaVac vaccination. *J. Infect. Dis.* **21**, 626 (2022).
- 16. Canaday, D. H. *et al.* COVID-19 vaccine booster dose needed to achieve Omicron-specific neutralisation in nursing home residents. *eBioMedicine* **80**, 104066 (2022).
- 17. Zuo, F. et al. Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant. Nat. Commun. 13(1), 2670 (2022).
- Atmar, R. L. et al. Heterologous SARS-CoV-2 booster vaccinations—Preliminary report. medRxiv https://doi.org/10.1101/2021. 10.10.21264827 (2021).
- Prasithsirikul, W. et al. Immunogenicity of ChAdOx1 nCoV-19 booster vaccination following two CoronaVac shots in healthcare workers. Vaccines 10(2), 217. https://doi.org/10.3390/vaccines10020217 (2022).
- Toledo-Romani, M. E. et al. Efficacy and safety of SOBERANA 02, a COVID-19 conjugate vaccine in heterologous three-dose combination. medRxiv https://doi.org/10.1101/2021.10.31.21265703 (2021).
- 21. Gorry, C. SOBERANA, Cuba's COVID-19 vaccine candidates: Dagmar García-Rivera PhD. MEDICC Rev. 22(4), 10-5 (2020).
- SOBÉRANA\* Plus [Internet]. Instituto Finlay de Vacunas Cuba. https://www.finlay.edu.cu/blog/wp-content/uploads/2021/12/ Commercial-file-SOBERANA-Plus-Eng.pdf (Accessed 11 April 2022).
- 23. Salehi-Vaziri, M. *et al.* SARS-CoV-2 presented moderately during two episodes of the infection with lack of antibody responses. *Virus Res.* **299**, 198421 (2021).
- Larijani, M. S., Pouriayevali, M. H., Sadat, S. M. & Ramezani, A. Production of recombinant HIV-1 p24-Nef protein in two forms as potential candidate vaccines in three vehicles. Curr. Drug Deliv. 17(5), 387–95 (2020).
- Larijani, M. S. et al. HIV-1 p24-nef DNA vaccine plus protein boost expands T-cell responses in BALB/c. Curr. Drug Deliv. 18(7), 1014–21 (2021).
- Eugenia Toledo-Romaní, M. *et al.* Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-PLUS: Double-blind, randomised, placebo-controlled phase 3 clinical trial. *medRxiv* 11, 22777 (2022).
- Toledo-Romani, M. E. et al. Safety and immunogenicity of anti-SARS CoV-2 conjugate vaccine SOBERANA 02 in a two-dose or three-dose heterologous scheme in adults: Phase IIb Clinical Trial. medRxiv 398, 1474 (2022).
- Kaabi, N. A. et al. Immunogenicity and safety of NVSI-06–07 as a heterologous booster after priming with BBIBP-CorV: A phase 2 trial. Signal Transduct. Target. Ther. 7(1), 172 (2022).
- Toledo-Romani, M. E. et al. Safety and immunogenicity of anti-SARS-CoV-2 heterologous scheme with SOBERANA 02 and SOBERANA Plus vaccines: Phase IIb clinical trial in adults. Med 3(11), 760–73.e5 (2022).
- Manenti, A. et al. Evaluation of SARS-CoV-2 neutralizing antibodies using a CPE-based colorimetric live virus micro-neutralization assay in human serum samples. J. Med. Virol. 92(10), 2096–104 (2020).

#### Acknowledgements

We would like to thank Pasteur Institute of Iran to support this study (Grant No. 2127).

#### **Author contributions**

A.R. designed the study and contributed to data interpretation and critical writing and revision of the manuscript; R.S. conceived and designed the study; S.H.M. analyzed and interpreted the data and designed the methodology and diagrams; S.D. performed the participants handling and visiting.; D.D. contributed to data interpretation; M.S.L. wrote the original draft, revised the manuscript and provided the data; S.E. provided the data and methodology and revised the manuscript; E.M. analyzed and interpreted the data and revised the manuscript; A.O. contributed to data interpretation; M.S.V. contributed to data interpretation; A.B. performed the assays and managed the laboratory tests; Gh.Z. performed the participants handling and visiting; L.M. performed the data collection; F.A. contributed to data collection; F.B.A. provided the data and methodology and revised the manuscript; P.M. performed the participants handling and visiting; Z.T. performed the data collection; A.B. conceived and designed the study.

### **Competing interests**

The authors declare no competing interests.

### Additional information

**Supplementary Information** The online version contains supplementary material available at https://doi.org/10.1038/s41598-023-35147-y.

Correspondence and requests for materials should be addressed to M.S.L. or A.B.

Reprints and permissions information is available at www.nature.com/reprints.

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2023

### Terms and Conditions

Springer Nature journal content, brought to you courtesy of Springer Nature Customer Service Center GmbH ("Springer Nature").

Springer Nature supports a reasonable amount of sharing of research papers by authors, subscribers and authorised users ("Users"), for smallscale personal, non-commercial use provided that all copyright, trade and service marks and other proprietary notices are maintained. By accessing, sharing, receiving or otherwise using the Springer Nature journal content you agree to these terms of use ("Terms"). For these purposes, Springer Nature considers academic use (by researchers and students) to be non-commercial.

These Terms are supplementary and will apply in addition to any applicable website terms and conditions, a relevant site licence or a personal subscription. These Terms will prevail over any conflict or ambiguity with regards to the relevant terms, a site licence or a personal subscription (to the extent of the conflict or ambiguity only). For Creative Commons-licensed articles, the terms of the Creative Commons license used will apply.

We collect and use personal data to provide access to the Springer Nature journal content. We may also use these personal data internally within ResearchGate and Springer Nature and as agreed share it, in an anonymised way, for purposes of tracking, analysis and reporting. We will not otherwise disclose your personal data outside the ResearchGate or the Springer Nature group of companies unless we have your permission as detailed in the Privacy Policy.

While Users may use the Springer Nature journal content for small scale, personal non-commercial use, it is important to note that Users may not:

- 1. use such content for the purpose of providing other users with access on a regular or large scale basis or as a means to circumvent access control;
- 2. use such content where to do so would be considered a criminal or statutory offence in any jurisdiction, or gives rise to civil liability, or is otherwise unlawful;
- 3. falsely or misleadingly imply or suggest endorsement, approval, sponsorship, or association unless explicitly agreed to by Springer Nature in writing;
- 4. use bots or other automated methods to access the content or redirect messages
- 5. override any security feature or exclusionary protocol; or
- 6. share the content in order to create substitute for Springer Nature products or services or a systematic database of Springer Nature journal content.

In line with the restriction against commercial use, Springer Nature does not permit the creation of a product or service that creates revenue, royalties, rent or income from our content or its inclusion as part of a paid for service or for other commercial gain. Springer Nature journal content cannot be used for inter-library loans and librarians may not upload Springer Nature journal content on a large scale into their, or any other, institutional repository.

These terms of use are reviewed regularly and may be amended at any time. Springer Nature is not obligated to publish any information or content on this website and may remove it or features or functionality at our sole discretion, at any time with or without notice. Springer Nature may revoke this licence to you at any time and remove access to any copies of the Springer Nature journal content which have been saved.

To the fullest extent permitted by law, Springer Nature makes no warranties, representations or guarantees to Users, either express or implied with respect to the Springer nature journal content and all parties disclaim and waive any implied warranties or warranties imposed by law, including merchantability or fitness for any particular purpose.

Please note that these rights do not automatically extend to content, data or other material published by Springer Nature that may be licensed from third parties.

If you would like to use or distribute our Springer Nature journal content to a wider audience or on a regular basis or in any other manner not expressly permitted by these Terms, please contact Springer Nature at

onlineservice@springernature.com